SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae

Journal of Clinical Microbiology

Volumn 43, Issue 10, 2005, Pages 5058-5064

  Szabó, Dóra ^a,b   Bonomo, Robert A ^c   Silveira, Fernanda ^a   Pasculle, A William ^a   Baxter, Carla ^a   Linden, Peter K ^a   Hujer, Andrea M ^c   Hujer, Kristine M ^c   Deeley, Kathleen ^a   Paterson, David L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLA GENE; CONTROLLED STUDY; DRUG USE; ENTEROBACTER CLOACAE; ENZYME RELEASE; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN IDENTIFICATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROBACTER CLOACAE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

ENTEROBACTER CLOACAE;

EID: 26944470372     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.10.5058-5064.2005     Document Type: Article

References (27)

1. Bell, J. M., J. D. Turnidge, R. N. Jones, and the SENTRY Asia-Pacific Participants. 2003. Prevalence of extended-spectrum β-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrob. Agents Chemother. 47:3989-3993.
2. Bonnet, R., J. L. M. Sampaio, R. Labia, C. De Champs, D. Sirot, C. Chanal, and J. Sirot. 2000. A novel CTX-M β-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob. Agents Chemother. 44:1936-1942.
3. Bouchillon, S. K., B. M. Johnson, D. J. Hoban, J. L. Johnson, M. J. Dowzicky, D. H. Wu, M. A. Visalli, and P. A. Bradford. 2004. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int. J. Antimicrob. Agents 24:119-124.
4. Chow, J. W., M. J. Fine, D. M. Shlaes, J. P. Quinn, D. C. Hooper, M. P. Johnson, R. Ramphal, M. M. Wagener, D. K. Miyashiro, and V. L. Yu. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:585-590.
5. D'Agata, E., L. Venkataraman, P. DeGirolami, L. Weigel, M. Samore, and F. Tenover. 1998. The molecular and clinical epidemiology of enterobacteriaceae- producing extended-spectrum beta-lactamase in a tertiary care hospital. J. Infect. 36:279-285.
6. Essack, S. Y., L. M. C. Hall, D. G. Pillay, M. L. McFadyen, and D. M. Livermore. 2001. Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum β-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob. Agents Chemother. 45:88-95.
7. Giakkoupi, P., L. S. Tzouvelekis, A. Tsakris, V. Loukova, D. Sofianou, and E. Tzelepi. 2000. IBC-1, a novel integron-associated class A β-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob. Agents Chemother. 44:2247-2253.
8. Ho, P. L., R. H. Shek, K. H. Chow, R. S. Duan, G. C. Mak, E. L. Lai, W. C. Yam, K. W. Tsang, and W. M. Lai. 2005. Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J. Antimicrob. Chemother. 55:326-332.
9. Jacoby, G. A., and L. S. Munoz-Price. 2005. The new beta-lactamases. N. Engl. J. Med. 352:380-391.
10. Kartali, G., E. Tzelepi, S. Pournaras, C. Kontopoulou, F. Kontos, D. Sofianou, A. N. Maniatis, and A. Tsakris. 2002. Outbreak of infections caused by Enterobacter cloacae producing the integron-associated β-lactamase IBC-1 in a neonatal intensive care unit of a Greek hospital. Antimicrob. Agents Chemother. 46:1577-1580.
11. Kaye, K. S., S. Cosgrove, A. Harris, G. M. Eliopoulos, and Y. Carmeli. 2001. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob. Agents Chemother. 45:2628-2630.
12. Kessler, R. E., M. Bies, R. E. Buck, D. R. Chisholm, T. A. Pursiano, Y. H. Tsai, M. Misiek, K. E. Price, and F. Leitner. 1985. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrob. Agents Chemother. 27:207-216.
13. Levison, M. E., Y. V. Mailapur, S. K. Pradhan, G. A. Jacoby, P. Adams, C. L. Emery, P. L. May, and P. G. Pitsakis. 2002. Regional occurrence of plasmid-mediated SHV-7, an extended-spectrum beta-lactamase, in Enterobacter cloacae in Philadelphia teaching hospitals. Clin. Infect. Dis. 35:1551-1554.
14. Munday, C. J., G. M. Whitehead, N. J. Todd, M. Campbell, and P. M. Hawkey. 2004. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK. J. Antimicrob. Chemother. 54:628-633.
15. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.
16. Pai, H., J. Y. Hong, J.-H. Byeon, Y.-K. Kim, and H.-J. Lee. 2004. High prevalence of extended-spectrum β-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob. Agents Chemother. 48:3159-3161.
17. Park, Y. J., S. Y. Park, E. J. Oh, J. J. Park, K. Y. Lee, G. J. Woo, and K. Lee. 2005. Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn. Microbiol. Infect. Dis. 51:265-269.
18. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
19. Paterson, D. L., L. B. Rice, and R. A. Bonomo. 2001. Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae. Clin. Microbiol. Infect. 7:709-711.
20. Rhomberg, P. R., R. N. Jones, H. S. Sader, et al. 2004. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int. J. Antimicrob. Agents 23:52-59.
21. Rice, L. B., S. H. Willey, G. A. Papanicolaou, A. A. Medeiros, G. M. Eliopoulos, R. C. Moellering, Jr., and G. A. Jacoby. 1990. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. 34:2193-2199.
22. Sanders, C. C., W. E. Sanders, Jr., and R. V. Goering. 1982. In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob. Agents Chemother. 21:968-975.
23. Sanders, W. E., Jr., J. H. Tenney, and R. E. Kessler. 1996. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin. Infect. Dis. 23:454-461.
24. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
25. Tsuji, A., A. Maniatis, M. A. Bertram, and L. S. Young. 1985. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents. Antimicrob. Agents Chemother. 27:515-519.
26. Vuye, A., and J. Pijck. 1985. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrob. Agents Chemother. 27: 574-577.
27. Zanetti, G., F. Bally, G. Greub, J. Garbino, T. Kinge, D. Lew, J.-A. Romand, J. Bille, D. Aymon, L. Stratchounski, L. Krawczyk, E. Rubinstein, M.-D. Schaller, R. Chiolero, M.-P. Glauser, A. Cometta, and the Cefepime Study Group. 2003. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob. Agents Chemother. 47: 3442-3447.